Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gorelick

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Clinical Chemistry|October 17, 2009
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THCEugene W Schwilke, David M Schwope, Erin L Karschner, et al.
Journal of Analytical Toxicology|October 31, 2009
Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humansTsadik T Abraham, Allan J Barnes, Ross H Lowe, et al.
Analytical and Bioanalytical Chemistry|November 16, 2013
3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administrationRebecca L Hartman, Nathalie A Desrosiers, Allan J Barnes, et al.
Clinical Pharmacology and Therapeutics|January 30, 2004
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependenceIvan D Montoya, David A Gorelick, Kenzie L Preston, et al.
Biological Psychiatry|June 29, 2010
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatientsUdi E Ghitza, Kenzie L Preston, David H Epstein, et al.
Pharmacology, Biochemistry, and Behavior|November 1, 1994
Lack of evidence for context-dependent cocaine-induced sensitization in humans: preliminary studiesR B Rothman, D A Gorelick, M H Baumann, et al.
Journal of Analytical Toxicology|October 18, 2012
Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokersDavid A Gorelick, Robert S Goodwin, Eugene Schwilke, et al.
The Journal of Trauma|January 7, 1998
The accuracy of the CAGE, the Brief Michigan Alcoholism Screening Test, and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholismC A Soderstrom, G S Smith, J A Kufera, et al.
Schizophrenia Research|December 6, 2011
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trialDouglas L Boggs, Deanna L Kelly, Robert P McMahon, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
Antagonist-elicited cannabis withdrawal in humansDavid A Gorelick, Robert S Goodwin, Eugene Schwilke, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Clinical Chemistry|October 17, 2009
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THCEugene W Schwilke, David M Schwope, Erin L Karschner, et al.
Journal of Analytical Toxicology|October 31, 2009
Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humansTsadik T Abraham, Allan J Barnes, Ross H Lowe, et al.
Analytical and Bioanalytical Chemistry|November 16, 2013
3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administrationRebecca L Hartman, Nathalie A Desrosiers, Allan J Barnes, et al.
Clinical Pharmacology and Therapeutics|January 30, 2004
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependenceIvan D Montoya, David A Gorelick, Kenzie L Preston, et al.
Biological Psychiatry|June 29, 2010
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatientsUdi E Ghitza, Kenzie L Preston, David H Epstein, et al.
Pharmacology, Biochemistry, and Behavior|November 1, 1994
Lack of evidence for context-dependent cocaine-induced sensitization in humans: preliminary studiesR B Rothman, D A Gorelick, M H Baumann, et al.
Journal of Analytical Toxicology|October 18, 2012
Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokersDavid A Gorelick, Robert S Goodwin, Eugene Schwilke, et al.
The Journal of Trauma|January 7, 1998
The accuracy of the CAGE, the Brief Michigan Alcoholism Screening Test, and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholismC A Soderstrom, G S Smith, J A Kufera, et al.
Schizophrenia Research|December 6, 2011
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trialDouglas L Boggs, Deanna L Kelly, Robert P McMahon, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
Antagonist-elicited cannabis withdrawal in humansDavid A Gorelick, Robert S Goodwin, Eugene Schwilke, et al.
Pageof 23